Lieff Cabraser Reminds Questcor Pharmaceuticals, Inc. Investors Of Upcoming Deadline In Class Action Lawsuits

Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the November 26, 2012 deadline to move for appointment as lead plaintiff in the securities class litigation against Questcor Pharmaceuticals, Inc. (“Questcor” or the “Company”) (NASDAQ: QCOR), brought on behalf of all persons who purchased or otherwise acquired the securities of Questcor between April 4, 2011 and September 21, 2012, inclusive (the “Class Period”).

If you purchased or otherwise acquired Questcor securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 26, 2012. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Questcor shareholders who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon Lee of Lieff Cabraser toll-free at 1 [phone].

The complaints charge Questcor and certain of its senior executives with violations of the Securities Exchange Act of 1934. Questcor is a California-based biopharmaceutical company. The Company’s primary product is H.P. Acthar Gel (“Acthar”), an injectable drug approved by the U. S. Food and Drug Administration (“FDA”) for the treatment of 19 conditions, including multiple scelorosis (“MS”), nephrotic syndrome and infantile spasms.

On September 19, 2012, Citron Research reported that Aetna Inc. (“Aetna”), one of the nation’s largest insurance companies, had revised its policy regarding Acthar, extensively limiting coverage for the drug. Aetna had engaged in a review of the 19 indications for which the FDA had approved Acthar and determined that clinical research suggested the drug is only “medically necessary” for West syndrome, a rare condition that causes infantile spasms, and not for other indications, such as MS. On this news, the price of Questcor’s common stock fell $24.17 per share to close at $26.35 per share on September 19, 2012, a one-day decline of nearly 48%.

1 2 Next › Last »